Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchUnknownNCT03497819
What this trial is testing

Autologous CARTmeso/19 Against Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
First Affiliated Hospital of Wenzhou Medical University 10
Early research (Phase 1)Study completedNCT02315612
What this trial is testing

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Who this might be right for
NHLLarge Cell LymphomaFollicular Lymphoma+7 more
National Cancer Institute (NCI) 134
Testing effectiveness (Phase 2)Ended earlyNCT05972720
What this trial is testing

Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
CancerRelapsed/Refractory Large B-cell Lymphoma (LBCL)
CARGO Therapeutics 101
Early research (Phase 1)WithdrawnNCT03768310
What this trial is testing

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

Who this might be right for
Non-hodgkin LymphomaAcute Lymphoblastic Leukemia
Baylor College of Medicine
Testing effectiveness (Phase 2)Looking for participantsNCT07510815
What this trial is testing

Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma

Who this might be right for
Malignant Pleural Mesotheliomas
Beijing Biotech 36
Testing effectiveness (Phase 2)Study completedNCT04340167
What this trial is testing

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia
Beijing Boren Hospital 14
Early research (Phase 1)Ended earlyNCT02744287
What this trial is testing

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Who this might be right for
Metastatic Castration-resistant Prostate CancerMetastatic Prostate Cancer
Regeneron Pharmaceuticals 52
Testing effectiveness (Phase 2)Looking for participantsNCT06698484
What this trial is testing

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Who this might be right for
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
National University of Malaysia 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06552572
What this trial is testing

Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy

Who this might be right for
Diffuse Large B Cell Lymphoma
Samsung Medical Center 30
Testing effectiveness (Phase 2)Ended earlyNCT07193966
What this trial is testing

NG2 and DLL3 CAR-T Cells Targeting Melanoma

Who this might be right for
Melanoma
Shenzhen Geno-Immune Medical Institute 100
Early research (Phase 1)Active Not RecruitingNCT05507827
What this trial is testing

Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

Who this might be right for
Lymphoid Leukemia
Stanford University 22
Early research (Phase 1)Looking for participantsNCT06500819
What this trial is testing

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

Who this might be right for
NeuroblastomaSarcomaOsteosarcoma
Stanford University 41
Early research (Phase 1)WithdrawnNCT03904069
What this trial is testing

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Amgen
Early research (Phase 1)Looking for participantsNCT07715630
What this trial is testing

In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Chongqing Precision Biotech Co., Ltd 15
Early research (Phase 1)Looking for participantsNCT06043466
What this trial is testing

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Who this might be right for
Colorectal CancerEsophagus CancerGastric Cancer+4 more
Chongqing Precision Biotech Co., Ltd 30
Early research (Phase 1)UnknownNCT04500431
What this trial is testing

Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Who this might be right for
Multiple Myeloma
Shanghai Tongji Hospital, Tongji University School of Medicine 10
Early research (Phase 1)Looking for participantsNCT07297667
What this trial is testing

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Who this might be right for
Alveolar Soft Part SarcomaRenal Cell CarcinomaTriple Negative Breast Cancer
Canadian Cancer Trials Group 30
Testing effectiveness (Phase 2)UnknownNCT02081937
What this trial is testing

CART-19 Immunotherapy in Mantle Cell Lymphoma

Who this might be right for
Hematopoietic/Lymphoid CancerNon-hodgkin Lymphoma,B CellMantle Cell Lymphoma
Chinese PLA General Hospital 2
Testing effectiveness (Phase 2)Looking for participantsNCT05648019
What this trial is testing

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Who this might be right for
Lymphoblastic LeukemiaLymphoblastic Leukemia in ChildrenLymphoblastic Leukemia, Acute Adult+3 more
KK Women's and Children's Hospital 40
Early research (Phase 1)Study completedNCT01109095
What this trial is testing

CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM

Who this might be right for
Glioblastoma Multiforme (GBM)
Baylor College of Medicine 16
Next Page